Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma

Fig. 2

A Paraprotein results over time for patient achieving prolonged period of disease stabilisation on NMP treatment. NMP dose levels are indicated at the top of the graph. B–G Maintenance of immune cell subsets in the same patient from pre-treatment (PRE) through to cycle 12 on NMP therapy. B T cells (CD3+CD19−), C B cells (CD19+CD3−) and D NK cells (CD56+CD3−CD19−) are shown as percentage of live lymphocytes; E immature (CD16−CD56hi), F regulatory (CD16−CD56+), and G mature (CD16+CD56+) NK cell subsets are shown as percentage of live NK cells. RDKm, lenalidomide, dexamethasone, KappaMab

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us